Ibogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac Dysrhythmias.
Grogan J, Gerona R, Snow JW, Kao L.
J Emerg Med · journal article; case reports · DOI 10.1016/j.jemermed.2019.06.052 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för ibogaine. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
13 hitsBiosynthesis of an Anti-Addiction Agent from the Iboga Plant.
Farrow SC, Kamileen MO, Caputi L, Bussey K, Mundy JEA, McAtee RC, Stephenson CRJ, O'Connor SE.
J Am Chem Soc · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; rapid-communication; journal article · DOI 10.1021/jacs.9b05999Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder.
Brown TK, Noller GE, Denenberg JO.
J Psychoactive Drugs · multicenter study; journal article; observational study · DOI 10.1080/02791072.2019.1598603Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits.
Marton S, González B, Rodríguez-Bottero S, Miquel E, Martínez-Palma L, Pazos M, Prieto JP, Rodríguez P, Sames D, Seoane G, Scorza C, Cassina P, Carrera I.
Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2019.00193Morphing of Ibogaine: A Successful Attempt into the Search for Sigma-2 Receptor Ligands.
Floresta G, Dichiara M, Gentile D, Prezzavento O, Marrazzo A, Rescifina A, Amata E.
Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms20030488A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.
Barsuglia JP, Polanco M, Palmer R, Malcolm BJ, Kelmendi B, Calvey T.
Prog Brain Res · research support, non-u.s. gov't; journal article · DOI 10.1016/bs.pbr.2018.08.002Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers.
Corkery JM.
Prog Brain Res · review; journal article · DOI 10.1016/bs.pbr.2018.08.005DARK Classics in Chemical Neuroscience: Ibogaine.
Wasko MJ, Witt-Enderby PA, Surratt CK.
ACS Chem Neurosci · historical article; review; journal article · DOI 10.1021/acschemneuro.8b00294Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review.
Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V.
Hum Exp Toxicol · review; journal article · DOI 10.1177/0960327107087802Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter.
Jacobs MT, Zhang YW, Campbell SD, Rudnick G.
J Biol Chem · journal article; research support, n.i.h., extramural · DOI 10.1074/jbc.m704456200Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors.
Layer RT, Skolnick P, Bertha CM, Bandarage UK, Kuehne ME, Popik P.
Eur J Pharmacol · journal article · DOI 10.1016/0014-2999(96)00304-4Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin.
Mash DC, Staley JK, Baumann MH, Rothman RB, Hearn WL.
Life Sci · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1016/0024-3205(95)00273-9The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex.
Popik P, Layer RT, Skolnick P.
Psychopharmacology (Berl) · journal article · DOI 10.1007/bf02245000